JP2015522540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522540A5 JP2015522540A5 JP2015512841A JP2015512841A JP2015522540A5 JP 2015522540 A5 JP2015522540 A5 JP 2015522540A5 JP 2015512841 A JP2015512841 A JP 2015512841A JP 2015512841 A JP2015512841 A JP 2015512841A JP 2015522540 A5 JP2015522540 A5 JP 2015522540A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- seq
- adjuvant
- hsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 29
- 230000002163 immunogen Effects 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000000240 adjuvant Effects 0.000 claims description 8
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 101710027020 CD46 Proteins 0.000 claims description 4
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 claims description 4
- 101700006250 UL19 Proteins 0.000 claims description 4
- 108091006028 chimera Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 101700009157 CVC2 Proteins 0.000 claims description 2
- 101710037585 IL45_03835 Proteins 0.000 claims description 2
- 229940031439 Squalene Drugs 0.000 claims description 2
- 101700034270 UL25 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000023 polynucleotide Polymers 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940079593 drugs Drugs 0.000 description 1
Description
本発明の実施形態において、例えば以下の項目が提供される。
(項目1)
(a)配列番号4のアミノ酸1〜450のうちの少なくとも75%が欠けており、また配列番号4の1055〜1374のアミノ酸のうちの少なくとも75%が欠けている、UL19ポリペプチドの免疫原性断片、
(b)配列番号12に記載される配列、
(c)少なくとも15個の隣接アミノ酸にわたり少なくとも85%のアミノ酸同一性を保持する、(a)または(b)の免疫原性変異体、
(d)(a)または(b)の免疫原性断片、および
(e)(a)、(b)、(c)、または(d)のキメラ融合物から成る群から選択される、HSV−2ポリペプチドの免疫原性断片。
(項目2)
項目1に記載のポリペプチドをコードする、単離されたポリヌクレオチド。
(項目3)
免疫原性薬学的組成物であって、
(i)
(a)配列番号4のアミノ酸1〜450のうちの少なくとも75%が欠けており、また配列番号4の1055〜1374のアミノ酸のうちの少なくとも75%が欠けている、UL19ポリペプチドの免疫原性断片、
(b)配列番号12に記載される配列、
(c)少なくとも15個の隣接アミノ酸にわたり少なくとも85%のアミノ酸同一性を保持する、(a)または(b)の免疫原性変異体、
(d)(a)または(b)の免疫原性断片、および
(e)(a)、(b)、または(c)のキメラ融合物から成る群から選択される、HSV−2ポリペプチドの免疫原性断片と、
(ii) 任意に、先天性免疫を活性化する薬剤と、
(iii) 薬学的に許容される担体と、を含む、組成物。
(項目4)
UL25またはその免疫原性断片をさらに含む、項目3に記載の組成物。
(項目5)
gD2またはその免疫原性断片をさらに含む、項目3および4のいずれか1項に記載の組成物。
(項目6)
前記薬剤は、アジュバントである、項目3〜5のいずれかに記載の組成物。
(項目7)
前記アジュバントは、GLAである、項目6に記載の組成物。
(項目8)
前記GLAは、水中油型エマルジョンの形態であるか、または水性形態である、項目7に記載の組成物。
(項目9)
前記水中油型エマルジョンは、スクアレンを含む、項目8に記載の組成物。
(項目10)
対象においてHSV−2感染を治療するための方法であって、前記対象に、項目3〜9のいずれか1項に記載の組成物を投与することを含む、方法。
(項目11)
対象において免疫応答を生じさせる方法であって、前記対象に、項目3〜9のいずれか1項に記載の組成物を投与することを含む、方法。
(項目12)
対象に、HSV−2に対して免疫付与するための方法であって、前記対象に、項目3〜9のいずれか1項に記載の組成物を投与することを含む、方法。
(項目13)
前記投与経路が、皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内である、項目9〜12のいずれか1項に記載の方法。
(項目14)
前記対象に、項目3〜9のいずれか1項に記載の第2、第3、または第4の組成物を投与することをさらに含む、項目9〜13のいずれかに記載の方法。
本発明のこれらのおよび他の態様および実施形態は、以下の詳細な説明および添付の図面への参照により、明らかになるであろう。
(項目1)
(a)配列番号4のアミノ酸1〜450のうちの少なくとも75%が欠けており、また配列番号4の1055〜1374のアミノ酸のうちの少なくとも75%が欠けている、UL19ポリペプチドの免疫原性断片、
(b)配列番号12に記載される配列、
(c)少なくとも15個の隣接アミノ酸にわたり少なくとも85%のアミノ酸同一性を保持する、(a)または(b)の免疫原性変異体、
(d)(a)または(b)の免疫原性断片、および
(e)(a)、(b)、(c)、または(d)のキメラ融合物から成る群から選択される、HSV−2ポリペプチドの免疫原性断片。
(項目2)
項目1に記載のポリペプチドをコードする、単離されたポリヌクレオチド。
(項目3)
免疫原性薬学的組成物であって、
(i)
(a)配列番号4のアミノ酸1〜450のうちの少なくとも75%が欠けており、また配列番号4の1055〜1374のアミノ酸のうちの少なくとも75%が欠けている、UL19ポリペプチドの免疫原性断片、
(b)配列番号12に記載される配列、
(c)少なくとも15個の隣接アミノ酸にわたり少なくとも85%のアミノ酸同一性を保持する、(a)または(b)の免疫原性変異体、
(d)(a)または(b)の免疫原性断片、および
(e)(a)、(b)、または(c)のキメラ融合物から成る群から選択される、HSV−2ポリペプチドの免疫原性断片と、
(ii) 任意に、先天性免疫を活性化する薬剤と、
(iii) 薬学的に許容される担体と、を含む、組成物。
(項目4)
UL25またはその免疫原性断片をさらに含む、項目3に記載の組成物。
(項目5)
gD2またはその免疫原性断片をさらに含む、項目3および4のいずれか1項に記載の組成物。
(項目6)
前記薬剤は、アジュバントである、項目3〜5のいずれかに記載の組成物。
(項目7)
前記アジュバントは、GLAである、項目6に記載の組成物。
(項目8)
前記GLAは、水中油型エマルジョンの形態であるか、または水性形態である、項目7に記載の組成物。
(項目9)
前記水中油型エマルジョンは、スクアレンを含む、項目8に記載の組成物。
(項目10)
対象においてHSV−2感染を治療するための方法であって、前記対象に、項目3〜9のいずれか1項に記載の組成物を投与することを含む、方法。
(項目11)
対象において免疫応答を生じさせる方法であって、前記対象に、項目3〜9のいずれか1項に記載の組成物を投与することを含む、方法。
(項目12)
対象に、HSV−2に対して免疫付与するための方法であって、前記対象に、項目3〜9のいずれか1項に記載の組成物を投与することを含む、方法。
(項目13)
前記投与経路が、皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内である、項目9〜12のいずれか1項に記載の方法。
(項目14)
前記対象に、項目3〜9のいずれか1項に記載の第2、第3、または第4の組成物を投与することをさらに含む、項目9〜13のいずれかに記載の方法。
本発明のこれらのおよび他の態様および実施形態は、以下の詳細な説明および添付の図面への参照により、明らかになるであろう。
Claims (25)
- (a)配列番号4のアミノ酸1〜450のうちの少なくとも75%が欠けており、また配列番号4の1055〜1374のアミノ酸のうちの少なくとも75%が欠けている、UL19ポリペプチドの免疫原性断片、
(b)配列番号12に記載される配列、
(c)配列の全長にわたり少なくとも85%のアミノ酸同一性を保持する、(a)または(b)の免疫原性変異体、および
(d)(a)、(b)、または(c)のキメラ融合物から成る群から選択される、HSV−2ポリペプチドの免疫原性断片。 - 請求項1に記載のポリペプチドをコードする、単離されたポリヌクレオチド。
- 免疫原性薬学的組成物であって、
(i)
(a)配列番号4のアミノ酸1〜450のうちの少なくとも75%が欠けており、また配列番号4の1055〜1374のアミノ酸のうちの少なくとも75%が欠けている、UL19ポリペプチドの免疫原性断片、
(b)配列番号12に記載される配列、
(c)配列の全長にわたり少なくとも85%のアミノ酸同一性を保持する、(a)または(b)の免疫原性変異体、および
(d)(a)、(b)、または(c)のキメラ融合物から成る群から選択される、HSV−2ポリペプチドの免疫原性断片と、
(ii) 任意に、先天性免疫を活性化する薬剤と、
(iii) 薬学的に許容される担体と、を含む、組成物。 - UL25またはその免疫原性断片あるいはgD2またはその免疫原性断片をさらに含む、請求項3に記載の組成物。
- gD2またはその免疫原性断片をさらに含む、請求項3に記載の組成物。
- 前記薬剤は、アジュバントである、請求項3に記載の組成物。
- 前記薬剤は、アジュバントである、請求項4に記載の組成物。
- 前記薬剤は、アジュバントである、請求項5に記載の組成物。
- 前記アジュバントは、GLAである、請求項6に記載の組成物。
- 前記アジュバントは、GLAである、請求項7に記載の組成物。
- 前記アジュバントは、GLAである、請求項8に記載の組成物。
- 前記GLAは、水中油型エマルジョンの形態であるか、または水性形態である、請求項9〜11のいずれか1項に記載の組成物。
- 前記水中油型エマルジョンは、スクアレンを含む、請求項12に記載の組成物。
- 対象においてHSV−2感染を治療するための医薬の製造のための請求項3〜11のいずれか1項に記載の組成物の使用。
- 対象においてHSV−2に対する免疫応答を生じさせるための医薬の製造のための請求項3〜11のいずれか1項に記載の組成物の使用。
- 対象に、HSV−2に対して免疫付与するための医薬の製造のための請求項3〜11のいずれか1項に記載の組成物の使用。
- 投与経路が、皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内である、請求項14に記載の使用。
- 投与経路が、皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内である、請求項15に記載の使用。
- 投与経路が、皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内である、請求項16に記載の使用。
- 対象においてHSV−2感染を治療するための請求項3〜11のいずれか1項に記載の組成物。
- 対象においてHSV−2に対する免疫応答を生じさせるための請求項3〜11のいずれか1項に記載の組成物。
- 対象に、HSV−2に対して免疫付与するための請求項3〜11のいずれか1項に記載の組成物。
- 皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内投与されることを特徴とする、請求項20に記載の組成物。
- 皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内投与されることを特徴とする、請求項21に記載の組成物。
- 皮内、粘膜、筋肉内、皮下、舌下、直腸内、または膣内投与されることを特徴とする、請求項22に記載の組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647764P | 2012-05-16 | 2012-05-16 | |
US61/647,764 | 2012-05-16 | ||
US201261679387P | 2012-08-03 | 2012-08-03 | |
US61/679,387 | 2012-08-03 | ||
US201261714158P | 2012-10-15 | 2012-10-15 | |
US61/714,158 | 2012-10-15 | ||
PCT/US2013/041364 WO2013173590A1 (en) | 2012-05-16 | 2013-05-16 | Vaccines for hsv-2 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018019053A Division JP2018076381A (ja) | 2012-05-16 | 2018-02-06 | Hsv−2のためのワクチン |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015522540A JP2015522540A (ja) | 2015-08-06 |
JP2015522540A5 true JP2015522540A5 (ja) | 2016-06-23 |
JP6619648B2 JP6619648B2 (ja) | 2019-12-11 |
Family
ID=48471140
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015512841A Expired - Fee Related JP6619648B2 (ja) | 2012-05-16 | 2013-05-16 | Hsv−2のためのワクチン |
JP2018019053A Withdrawn JP2018076381A (ja) | 2012-05-16 | 2018-02-06 | Hsv−2のためのワクチン |
JP2019133412A Active JP6790189B2 (ja) | 2012-05-16 | 2019-07-19 | Hsv−2のためのワクチン |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018019053A Withdrawn JP2018076381A (ja) | 2012-05-16 | 2018-02-06 | Hsv−2のためのワクチン |
JP2019133412A Active JP6790189B2 (ja) | 2012-05-16 | 2019-07-19 | Hsv−2のためのワクチン |
Country Status (26)
Country | Link |
---|---|
US (4) | US9555099B2 (ja) |
EP (2) | EP2850431B1 (ja) |
JP (3) | JP6619648B2 (ja) |
KR (1) | KR102136433B1 (ja) |
CN (2) | CN107540730B (ja) |
AU (2) | AU2013262691B2 (ja) |
BR (1) | BR112014028476A2 (ja) |
CA (1) | CA2873629A1 (ja) |
CY (1) | CY1120489T1 (ja) |
DK (1) | DK2850431T3 (ja) |
EA (1) | EA034351B1 (ja) |
ES (2) | ES2673556T3 (ja) |
HK (1) | HK1202627A1 (ja) |
HR (1) | HRP20181102T1 (ja) |
HU (1) | HUE039215T2 (ja) |
IL (2) | IL235633B (ja) |
LT (1) | LT2850431T (ja) |
MX (1) | MX350274B (ja) |
NZ (1) | NZ701881A (ja) |
PL (1) | PL2850431T3 (ja) |
PT (1) | PT2850431T (ja) |
RS (1) | RS57420B1 (ja) |
SG (1) | SG11201407586WA (ja) |
SI (1) | SI2850431T1 (ja) |
WO (1) | WO2013173590A1 (ja) |
ZA (1) | ZA201408456B (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201404711WA (en) | 2012-02-16 | 2014-09-26 | Vlp Therapeutics Llc | Virus like particle composition |
PL2850431T3 (pl) | 2012-05-16 | 2018-09-28 | Immune Design Corp. | Szczepionki przeciwko HSV-2 |
WO2014164699A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
TWI676636B (zh) | 2013-07-12 | 2019-11-11 | Vlp醫療股份有限公司 | 包含pd-1抗原或pd-1配體抗原的類病毒粒子 |
US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
CN104694553B (zh) * | 2013-12-05 | 2018-04-17 | 长春百克生物科技股份公司 | 生殖器疱疹疫苗 |
US9616119B2 (en) * | 2014-03-24 | 2017-04-11 | University Of Kansas | Neuroattenuated herpes simplex virus |
US11071745B2 (en) | 2014-07-07 | 2021-07-27 | Elian Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
ES2964529T3 (es) * | 2014-07-07 | 2024-04-08 | Elian Llc | Profilaxis anti-VHS preexposición |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | 修飾エンベロープタンパク質e3を含むウイルス様粒子 |
CA2960102C (en) | 2014-09-11 | 2023-10-24 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
KR101962683B1 (ko) * | 2016-09-28 | 2019-03-27 | 주식회사 에스엘백시젠 | Hsv-2 감염 예방 및 치료용 dna 백신 |
WO2018140733A1 (en) * | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018186755A1 (en) * | 2017-04-04 | 2018-10-11 | Beagley Kenneth | Novel vaccine for the prevention or treatment of an infection caused by a herpes virus. |
EP3641810A4 (en) * | 2017-04-26 | 2021-08-18 | Modernatx, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
US11389529B2 (en) | 2017-07-13 | 2022-07-19 | City Of Hope | Expression system for expressing herpesvirus glycoprotein complexes |
EP3677592A4 (en) * | 2017-08-30 | 2021-06-09 | KM Biologics Co., Ltd. | MODIFIED HSV GD PROTEIN AND VACCINE CONTAINING IT |
US11213582B2 (en) * | 2018-08-08 | 2022-01-04 | The Regents Of The University Of California | Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits |
AU2021281314A1 (en) | 2020-05-29 | 2022-12-22 | Albert Einstein College Of Medicine | Methods of using HSV-2 single cycle virus delta-gD and HSV-2 recombinant glycoprotein D |
EP4225360A1 (en) | 2020-10-08 | 2023-08-16 | Virothera Limited | Vaccine compositions |
Family Cites Families (293)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4029762A (en) | 1971-11-17 | 1977-06-14 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Lipid A-preparation |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4420558A (en) | 1981-02-12 | 1983-12-13 | Janssen Pharmaceutica N.V. | Bright field light microscopic method of enumerating and characterizing subtypes of white blood cells and their precursors |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4762708A (en) | 1982-02-18 | 1988-08-09 | University Patents, Inc. | Materials and methods for herpes simplex virus vaccination |
US4709011A (en) | 1982-02-18 | 1987-11-24 | University Patents, Inc. | Materials and methods for herpes simplex virus vaccination |
US5478746A (en) | 1982-04-07 | 1995-12-26 | The United States Of America As Represented By The Department Of Health And Human Services | cDNA encoding attenuated cell culture adapted hepatitis A virus genome |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4420461A (en) | 1982-05-26 | 1983-12-13 | Ortho Diagnostic Systems Inc. | Agglutination-inhibition test kit for detecting immune complexes |
US4818694A (en) | 1982-07-20 | 1989-04-04 | American Cyanamid Company | Production of herpes simplex viral protein |
US4891315A (en) | 1982-10-25 | 1990-01-02 | American Cyanamid Company | Production of herpes simplex viral porteins |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
NZ209308A (en) | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
US7264817B1 (en) | 1983-08-30 | 2007-09-04 | Genentech, Inc. | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it |
US4743540A (en) | 1983-09-27 | 1988-05-10 | Memorial Sloan-Kettering Cancer Center | Method for diagnosis of subclassifications of common varied immunodeficiency disease group |
US5147785A (en) | 1983-11-01 | 1992-09-15 | Amtl Corporation | Method and apparatus for measuring the degree of reaction between a foreign entity and white blood cells |
US4614722A (en) | 1983-11-01 | 1986-09-30 | Pasula Mark J | Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies |
US4595654A (en) | 1983-11-07 | 1986-06-17 | Immunomedics Inc. | Method for detecting immune complexes in serum |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US4844894A (en) | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
US4629722A (en) | 1984-07-12 | 1986-12-16 | Ribi Immunochem Research, Inc. | Method of inhibiting the onset of acute radiation syndrome |
US5612041A (en) | 1984-07-17 | 1997-03-18 | Chiron Corporation | Recombinant herpes simplex gD vaccine |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4659659A (en) | 1985-01-22 | 1987-04-21 | Monsanto Company | Diagnostic method for diseases having an arthritic component |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4746742A (en) | 1985-11-28 | 1988-05-24 | Toho Yakuhin Kogyo Kabushiki Kaisha | Analogs of nonreducing monosaccharide moiety of lipid A |
US5976785A (en) | 1986-01-22 | 1999-11-02 | Institut Pasteur | Competitive assays for determining the effectiveness of a human immunodeficiency virus type 2 (HIV-2) antiviral agent, employing peptides and proteins of HIV-2 |
US5310651A (en) | 1986-01-22 | 1994-05-10 | Institut Pasteur | DNA probes of human immunodeficiency virus type 2 (HIV-2), and methods employing these probes for dectecting the presence of HIV-2 |
US6514691B1 (en) | 1986-01-22 | 2003-02-04 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2 |
US6054565A (en) | 1986-03-03 | 2000-04-25 | Institut Pasteur | Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2 |
US5169763A (en) | 1986-04-08 | 1992-12-08 | Transgene S.A., Institut Pasteur | Viral vector coding glycoprotein of HIV-1 |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5352449A (en) | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
JPH0755906B2 (ja) | 1986-07-01 | 1995-06-14 | 第一製薬株式会社 | ジサツカライド誘導体含有鎮痛剤 |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4948587A (en) | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2672290B1 (fr) | 1991-02-05 | 1995-04-21 | Pasteur Institut | Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t. |
US5565209A (en) | 1987-03-17 | 1996-10-15 | Akzo Nobel N.V. | Adjuvant mixture |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
US4780212A (en) | 1987-07-31 | 1988-10-25 | Massachusetts Institute Of Technology | Ultrasound enchancement of membrane permeability |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
EP0324455A3 (en) | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Novel polymeric immunological adjuvants |
GB2232892B (en) | 1988-02-23 | 1991-07-24 | John Mark Tucker | Occlusive body for administering a physiologically active substance |
EP0342926B1 (en) | 1988-05-17 | 1994-09-28 | Mycogen Plant Science, Inc. | Plant ubiquitin promoter system |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5888519A (en) | 1988-06-02 | 1999-03-30 | The United States Of America As Represented By The Secretary Of The Army | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
US5231168A (en) | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
EP0449856B1 (en) | 1988-12-16 | 2001-09-12 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom |
EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
DK0382271T3 (da) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler som adjuvanser i vacciner |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
SG48175A1 (en) | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US4981684A (en) | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US5149532A (en) | 1989-11-01 | 1992-09-22 | Cedars Sinai Medical Center | Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms |
US6120769A (en) | 1989-11-03 | 2000-09-19 | Immulogic Pharmaceutical Corporation | Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor |
US5298396A (en) | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
US5124141A (en) | 1990-06-14 | 1992-06-23 | Flow Incorporated | Method for diagnosing malaria |
US5162990A (en) | 1990-06-15 | 1992-11-10 | The United States Of America As Represented By The United States Navy | System and method for quantifying macrophage phagocytosis by computer image analysis |
US5709879A (en) | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
DE69233186T2 (de) | 1991-05-06 | 2004-06-03 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung |
EP1298211B1 (en) | 1991-07-19 | 2006-07-12 | The University Of Queensland | Polynucleotide segment of HPV16 Genome |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US5709860A (en) | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
HU220295B (hu) | 1991-07-25 | 2001-11-28 | Idec Pharmaceuticals Corp. | Antigénkészítmények és ezek alkalmazása citotoxikus T-limfocita reakciók indukálására |
US5530113A (en) | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
AU660325B2 (en) | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
US5149259A (en) | 1991-10-28 | 1992-09-22 | Jwp Air Technologies | Grateless regenerative incinerator |
ES2129461T3 (es) | 1991-11-16 | 1999-06-16 | Smithkline Beecham Biolog | Proteina hibrida entre cs de plasmodium y hbsag. |
US6057427A (en) | 1991-11-20 | 2000-05-02 | Trustees Of Dartmouth College | Antibody to cytokine response gene 2(CR2) polypeptide |
JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
US5286718A (en) | 1991-12-31 | 1994-02-15 | Ribi Immunochem Research, Inc. | Method and composition for ameliorating tissue damage due to ischemia and reperfusion |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
DE122007000096I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
US5679356A (en) | 1992-07-08 | 1997-10-21 | Schering Corporation | Use of GM-CSF as a vaccine adjuvant |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
US5411865A (en) | 1993-01-15 | 1995-05-02 | Iasys Corporation | Method of detecting anti-leishmania parasite antibodies |
PT1618888E (pt) | 1993-03-09 | 2011-04-08 | Univ Rochester | Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus |
CN1087176C (zh) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | 含有3-o脱酰基单磷酰脂a的疫苗制剂 |
US5532133A (en) | 1993-06-02 | 1996-07-02 | New York University | Plasmodium vivax blood stage antigens, PvESP-1, antibodies, and diagnostic assays |
JP3286030B2 (ja) | 1993-08-10 | 2002-05-27 | 株式会社東芝 | 保全管理装置および保全管理ガイド装置 |
US6106824A (en) | 1993-08-13 | 2000-08-22 | The Rockefeller University | Expression of growth associated protein B-50/GAP-43 in vitro and in vivo |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
EP0652600B1 (en) | 1993-11-02 | 1999-04-28 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing an aggregate of semiconductor micro-needles |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
US5693531A (en) | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
DE9319879U1 (de) | 1993-12-23 | 1994-03-17 | Inventa Ag | Sequentiell Coextrudierte Kühlflüssigkeitsleitung |
EP0737205A1 (en) | 1993-12-28 | 1996-10-16 | Chiron Mimotopes Pty. Ltd. | T-cell epitopes |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
ES2267100T5 (es) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | Oligonucleótidos inmunomoduladores. |
US7094767B2 (en) | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
US7037712B2 (en) | 1994-07-26 | 2006-05-02 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
SE9403137D0 (sv) | 1994-09-20 | 1994-09-20 | Perstorp Ab | Derivatives of carbohydrates and compositions containing them |
JP4418965B2 (ja) | 1994-09-23 | 2010-02-24 | タップイミューン・インコーポレイテッド | 内在性ペプチドを有するmhcクラスi分子の発現を増強する方法 |
EP1016418B1 (en) | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Host cell comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
ATE325875T1 (de) | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
US6096542A (en) | 1995-02-08 | 2000-08-01 | Takara Shuzo Co., Ltd. | Cancer control |
US5955087A (en) | 1995-02-24 | 1999-09-21 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US5912166A (en) | 1995-04-21 | 1999-06-15 | Corixa Corporation | Compounds and methods for diagnosis of leishmaniasis |
US6846489B1 (en) | 1995-04-25 | 2005-01-25 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
US5993800A (en) | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US6417172B1 (en) | 1995-06-05 | 2002-07-09 | Eisai Co., Ltd. | Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US6309847B1 (en) | 1995-07-05 | 2001-10-30 | Yeda Research And Development Co. Ltd. | Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
AU7254396A (en) | 1995-09-29 | 1997-04-17 | Eisai Research Institute | Method for treating alcoholic liver disease |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5846758A (en) | 1995-11-30 | 1998-12-08 | His Excellency Ghassan I. Shaker | Method for diagnosing autoimmune diseases |
US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
SE9600648D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Receptorbimdande enhet |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US5762943A (en) | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
WO1998001139A1 (en) | 1996-07-03 | 1998-01-15 | Eisai Co., Ltd. | Injections containing lipid a analogues and process for the preparation thereof |
US6093800A (en) | 1996-09-06 | 2000-07-25 | The Regents Of The University Of California | E25a protein, methods for production and use thereof |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
JP4111403B2 (ja) | 1996-10-11 | 2008-07-02 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫刺激ポリヌクレオチド/免疫調節分子複合体 |
JPH10131046A (ja) | 1996-10-29 | 1998-05-19 | Nikka Chem Co Ltd | 繊維の耐久性pH緩衝加工方法 |
CA2270282A1 (en) | 1996-11-04 | 1998-05-14 | Smithkline Beecham Corporation | Novel coding sequences from herpes simplex virus type-2 |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US7033598B2 (en) | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
DE19654221B4 (de) | 1996-12-23 | 2005-11-24 | Telefonaktiebolaget Lm Ericsson (Publ) | Leitungsanschlußschaltkreis |
EP0961830A1 (en) | 1997-01-29 | 1999-12-08 | Neurosearch A/S | EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
US6977073B1 (en) | 1997-02-07 | 2005-12-20 | Cem Cezayirli | Method for stimulating an immune response |
AR012035A1 (es) | 1997-02-25 | 2000-09-27 | Corixa Corp | Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico |
US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
CN1326564C (zh) | 1997-04-01 | 2007-07-18 | 科里克萨有限公司 | 单磷酰基脂质a的水性免疫佐剂组合物 |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
US7037510B2 (en) | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
US6555653B2 (en) | 1997-05-20 | 2003-04-29 | Corixa Corporation | Compounds for diagnosis of tuberculosis and methods for their use |
US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
WO1998058956A2 (en) | 1997-06-23 | 1998-12-30 | Ludwig Institute For Cancer Research | Methods for inducing an immune response involving prime-boost protocols |
CA2297374A1 (en) | 1997-07-21 | 1999-01-28 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
US6368604B1 (en) | 1997-09-26 | 2002-04-09 | University Of Maryland Biotechnology Institute | Non-pyrogenic derivatives of lipid A |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
KR100735653B1 (ko) | 1997-11-28 | 2007-07-06 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
US7012134B2 (en) | 1998-01-26 | 2006-03-14 | Human Genome Sciences, Inc. | Dendritic enriched secreted lymphocyte activation molecule |
DE19803453A1 (de) | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
DK1659179T3 (da) | 1998-02-05 | 2011-10-10 | Glaxosmithkline Biolog Sa | Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination |
JP2002502884A (ja) | 1998-02-12 | 2002-01-29 | アメリカン・サイアナミド・カンパニー | インターロイキン−12および単純ヘルペスウイルス抗原を含んでなるワクチン |
DE59913841D1 (de) | 1998-02-12 | 2006-10-26 | Infineon Technologies Ag | EEPROM und Verfahren zur Ansteuerung eines EEPROM |
US6596501B2 (en) | 1998-02-23 | 2003-07-22 | Fred Hutchinson Cancer Research Center | Method of diagnosing autoimmune disease |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
PL343429A1 (en) | 1998-03-09 | 2001-08-13 | Smithkline Beecham Biolog | Combined vaccine compositions |
WO1999051748A2 (en) | 1998-04-07 | 1999-10-14 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
GB2336310B (en) | 1998-04-14 | 2003-09-10 | Stowic Resources Ltd | Method of manufacturing transdermal patches |
WO1999053061A2 (en) | 1998-04-15 | 1999-10-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
JP2002513773A (ja) | 1998-05-07 | 2002-05-14 | コリクサ コーポレイション | アジュバント組成物及びその使用法 |
GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
CZ2001149A3 (cs) | 1998-07-14 | 2002-02-13 | Corixa Corporation | Prostředky a způsoby pro terapii a diagnostiku karcinomu prostaty |
EP1102790B1 (en) * | 1998-08-07 | 2014-05-07 | University of Washington | Immunological Herpes Simplex Virus antigens and methods for use thereof |
WO2000013029A1 (fr) | 1998-09-01 | 2000-03-09 | Eisai Co., Ltd | Procede pour evaluer des injections contenant des analogues de lipide a |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
US6375944B1 (en) | 1998-09-25 | 2002-04-23 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 |
WO2000018929A2 (en) | 1998-09-25 | 2000-04-06 | Smithkline Beecham Biologicals S.A. | Paramyxovirus vaccines |
US7001770B1 (en) | 1998-10-15 | 2006-02-21 | Canji, Inc. | Calpain inhibitors and their applications |
EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
US6261573B1 (en) | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
EP1141338A4 (en) | 1998-12-31 | 2002-09-25 | Arch Dev Corp | RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES |
US6512102B1 (en) | 1998-12-31 | 2003-01-28 | Chiron Corporation | Compositions and methods of diagnosis and treatment using casein kinase I |
WO2000042994A2 (en) | 1999-01-21 | 2000-07-27 | North Shore-Long Island Jewish Research Institute | Inhibition of bacterial dissemination |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
US20030170249A1 (en) | 1999-02-19 | 2003-09-11 | Hakomori Sen-Itiroh | Vaccines directed to cancer-associated carbohydrate antigens |
US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
ES2270817T3 (es) | 1999-04-07 | 2007-04-16 | Hiroshi Okamoto | Metodo para evaluar enfermedades autoinmunes, metodo para detectar autoanticuerpos de la proteina anti-reg y diagnosticos para enfermedades autoinmunes. |
KR100922031B1 (ko) | 1999-04-19 | 2009-10-19 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
US6685699B1 (en) | 1999-06-09 | 2004-02-03 | Spectrx, Inc. | Self-removing energy absorbing structure for thermal tissue ablation |
EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
WO2001014544A1 (en) | 1999-08-26 | 2001-03-01 | Biovitrum Ab | Novel response element |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US7084256B2 (en) | 1999-09-24 | 2006-08-01 | Large Scale Biology Corporation | Self antigen vaccines for treating B cell lymphomas and other cancers |
DE60031874D1 (de) | 1999-09-30 | 2006-12-28 | Univ Washington | Immunologisch relevante antigene aus herpes simplexvirus |
JP4162813B2 (ja) | 1999-10-28 | 2008-10-08 | 久光製薬株式会社 | イオントフォレーシス装置 |
US6218186B1 (en) | 1999-11-12 | 2001-04-17 | Trustees Of The University Of Pennsylvania | HIV-MSCV hybrid viral vector for gene transfer |
WO2001036433A2 (en) | 1999-11-15 | 2001-05-25 | Biomira, Inc. | Synthetic lipid-a analogs and uses thereof |
US20020064801A1 (en) | 1999-12-01 | 2002-05-30 | Ryan Jeffrey R. | Novel and practical serological assay for the clinical diagnosis of leishmaniasis |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US6587792B1 (en) | 2000-01-11 | 2003-07-01 | Richard A. Thomas | Nuclear packing efficiency |
GB0000891D0 (en) | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
WO2001055362A2 (en) | 2000-01-31 | 2001-08-02 | The Governement Of The United States Of America, As Represented By The Secretary, Departement Of Health & Human Services, The National Institutes Of Health | Hybrid adeno-retroviral vector for the transfection of cells |
EP1122542A1 (en) | 2000-02-01 | 2001-08-08 | Anda Biologicals S.A. | Method for the rapid detection of whole microorganisms on retaining membranes by use of chaotropic agents |
CN1606446A (zh) | 2000-05-19 | 2005-04-13 | 科里克萨有限公司 | 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法 |
US7125549B2 (en) | 2000-05-31 | 2006-10-24 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
US20030165819A1 (en) * | 2000-06-29 | 2003-09-04 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
US20030068327A1 (en) | 2000-06-29 | 2003-04-10 | Corixa Corporation | Compositions and methods for the diagnosis and threatment of herpes simplex virus infection |
DE10041515A1 (de) | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
US7060802B1 (en) | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
CA2436107C (en) | 2000-10-06 | 2012-05-22 | H. Henrich Paradies | Kyberdrug as autovaccines with immune-regulating effects |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
EP1889630B1 (en) | 2000-10-18 | 2011-11-23 | GlaxoSmithKline Biologicals S.A. | Vaccines comprising MAGE antigen linked to protein D fragment |
EP1423421A2 (en) | 2001-01-26 | 2004-06-02 | Walter Reed Army Institute of Research | Isolation and purification of p. falciparum merozoite protein-1 42 vaccine |
US6893820B1 (en) | 2001-01-31 | 2005-05-17 | The Ohio State University Research Foundation | Detection of methylated CpG rich sequences diagnostic for malignant cells |
GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
US7029685B2 (en) | 2001-03-26 | 2006-04-18 | The United States Of America As Represented By The Secretary Of The Army | Plasmodium falciparum AMA-1 protein and uses thereof |
CA2441952C (en) | 2001-03-26 | 2010-06-01 | Walter Reed Army Institute Of Research | Plasmodium falciparum ama-1 protein and uses thereof |
US6933123B2 (en) | 2001-04-05 | 2005-08-23 | Yao Xiong Hu | Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers |
US6844192B2 (en) | 2001-06-29 | 2005-01-18 | Wake Forest University | Adenovirus E4 protein variants for virus production |
EP1420821B8 (en) | 2001-07-31 | 2011-02-02 | University of Washington | Immunologically significant herpes simplex virus antigens and methods for using same |
US7727974B2 (en) | 2001-08-10 | 2010-06-01 | Eisai R & D Management Co., Ltd. | Methods of reducing the severity of mucositis |
WO2003021227A2 (en) | 2001-09-05 | 2003-03-13 | The Children's Hospital Of Philadelphia | Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
AU2002352913B2 (en) | 2001-11-30 | 2008-05-29 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen, and uses therefor |
US6752995B2 (en) | 2002-04-15 | 2004-06-22 | Board Of Regents, The University Of Texas System | Nucleic acid and polypeptide sequences useful as adjuvants |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
ATE457733T1 (de) | 2002-05-09 | 2010-03-15 | Oncothyreon Inc | Lipid-a- und andere kohlenhydrat-liganden-analoga |
US20080299140A1 (en) | 2002-05-24 | 2008-12-04 | The Regents Of The University Of California, | Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition |
ATE494907T1 (de) | 2002-07-18 | 2011-01-15 | Univ Washington | Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten |
US20050130132A1 (en) * | 2002-09-06 | 2005-06-16 | Day Craig H. | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
US7018345B2 (en) | 2002-12-06 | 2006-03-28 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
US20050123550A1 (en) | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
US20050244419A1 (en) | 2003-07-25 | 2005-11-03 | Pierre-Francois Tosi | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
FR2857875A1 (fr) | 2003-07-25 | 2005-01-28 | Univ Reims Champagne Ardenne | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
WO2006055729A1 (en) | 2004-11-16 | 2006-05-26 | Transcutaneous Technologies Inc. | Iontophoretic device and method for administering immune response-enhancing agents and compositions |
EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
JP5576610B2 (ja) * | 2006-02-20 | 2014-08-20 | フィロジカ リミテッド | ペプチド構造のライブラリーの構築およびスクリーニング方法 |
WO2008011609A2 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
LT2484375T (lt) * | 2006-09-26 | 2018-07-10 | Infectious Disease Research Institute | Vakcinos kompozicija, turinti sintetinio adjuvanto |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
US8563523B2 (en) | 2007-09-07 | 2013-10-22 | University Of Georgia Research Foundation, Inc. | Synthetic lipid A derivative |
HUE036103T2 (hu) | 2007-12-11 | 2018-06-28 | Univ North Carolina Chapel Hill | Polipurin szakaszon módosított retrovirális vektorok |
WO2010115172A2 (en) * | 2009-04-03 | 2010-10-07 | University Of Washington | Antigenic peptide of hsv-2 and methods for using same |
NZ597182A (en) | 2009-05-22 | 2014-07-25 | Genocea Biosciences Inc | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
SI2770061T1 (sl) | 2009-07-24 | 2019-02-28 | Immune Design Corp. | Neintegrirani lentiviralni vektorji |
US20130224236A1 (en) * | 2010-11-03 | 2013-08-29 | University Of Washington | Hsv-1 epitopes and methods for using same |
JP2014510721A (ja) * | 2011-02-15 | 2014-05-01 | イミューン デザイン コーポレイション | ベクターワクチンによる免疫原特異的免疫応答を強化するための方法 |
MX350795B (es) * | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
WO2012149307A2 (en) * | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
AU2012279154A1 (en) * | 2011-07-01 | 2014-02-20 | The Regents Of The University Of California | Herpes virus vaccine and methods of use |
AU2012340712B2 (en) | 2011-11-23 | 2017-09-14 | Genocea Biosciences, Inc. | Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
US9241988B2 (en) | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
PL2850431T3 (pl) * | 2012-05-16 | 2018-09-28 | Immune Design Corp. | Szczepionki przeciwko HSV-2 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
-
2013
- 2013-05-16 PL PL13724492T patent/PL2850431T3/pl unknown
- 2013-05-16 CN CN201710598216.6A patent/CN107540730B/zh not_active Expired - Fee Related
- 2013-05-16 CN CN201380036258.0A patent/CN104412108B/zh not_active Expired - Fee Related
- 2013-05-16 EA EA201492110A patent/EA034351B1/ru not_active IP Right Cessation
- 2013-05-16 CA CA2873629A patent/CA2873629A1/en not_active Abandoned
- 2013-05-16 NZ NZ701881A patent/NZ701881A/en not_active IP Right Cessation
- 2013-05-16 AU AU2013262691A patent/AU2013262691B2/en not_active Ceased
- 2013-05-16 WO PCT/US2013/041364 patent/WO2013173590A1/en active Application Filing
- 2013-05-16 RS RS20180792A patent/RS57420B1/sr unknown
- 2013-05-16 EP EP13724492.7A patent/EP2850431B1/en active Active
- 2013-05-16 HU HUE13724492A patent/HUE039215T2/hu unknown
- 2013-05-16 SI SI201331065T patent/SI2850431T1/en unknown
- 2013-05-16 PT PT137244927T patent/PT2850431T/pt unknown
- 2013-05-16 SG SG11201407586WA patent/SG11201407586WA/en unknown
- 2013-05-16 MX MX2014013921A patent/MX350274B/es active IP Right Grant
- 2013-05-16 EP EP18159552.1A patent/EP3388835B1/en active Active
- 2013-05-16 ES ES13724492.7T patent/ES2673556T3/es active Active
- 2013-05-16 ES ES18159552T patent/ES2787455T3/es active Active
- 2013-05-16 BR BR112014028476A patent/BR112014028476A2/pt not_active Application Discontinuation
- 2013-05-16 LT LTEP13724492.7T patent/LT2850431T/lt unknown
- 2013-05-16 KR KR1020147035363A patent/KR102136433B1/ko active IP Right Grant
- 2013-05-16 JP JP2015512841A patent/JP6619648B2/ja not_active Expired - Fee Related
- 2013-05-16 DK DK13724492.7T patent/DK2850431T3/en active
- 2013-05-16 US US13/895,888 patent/US9555099B2/en active Active
- 2013-05-16 US US13/895,858 patent/US9895435B2/en active Active
-
2014
- 2014-11-11 IL IL235633A patent/IL235633B/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08456A patent/ZA201408456B/en unknown
-
2015
- 2015-03-26 HK HK15103101.3A patent/HK1202627A1/xx not_active IP Right Cessation
-
2016
- 2016-12-14 US US15/378,864 patent/US10391164B2/en active Active
-
2018
- 2018-02-06 JP JP2018019053A patent/JP2018076381A/ja not_active Withdrawn
- 2018-07-12 CY CY20181100731T patent/CY1120489T1/el unknown
- 2018-07-13 HR HRP20181102TT patent/HRP20181102T1/hr unknown
-
2019
- 2019-03-20 AU AU2019201927A patent/AU2019201927A1/en not_active Abandoned
- 2019-06-05 IL IL267111A patent/IL267111B/en active IP Right Grant
- 2019-07-16 US US16/513,311 patent/US20200023057A1/en not_active Abandoned
- 2019-07-19 JP JP2019133412A patent/JP6790189B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015522540A5 (ja) | ||
HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
Lee et al. | A review of DNA vaccines against influenza | |
JP2015214545A5 (ja) | ||
JP2016506416A5 (ja) | ||
RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
RU2016145464A (ru) | Рекомбинантные вакцинные штаммы listeria и способы их получения | |
JP2010500399A5 (ja) | ||
JP2017513502A5 (ja) | ||
JP2008530245A5 (ja) | ||
IL276210B2 (en) | MERS-COV vaccine | |
JP2016539946A5 (ja) | ||
JP2013507907A5 (ja) | ||
EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
JP2017530124A5 (ja) | ||
JP2015514132A5 (ja) | ||
JP2020528911A5 (ja) | ||
JP2002542827A5 (ja) | ||
JP2012102105A5 (ja) | ||
JP2016520530A5 (ja) | ||
JP2013518052A5 (ja) | ||
MX2020012913A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
JP2016514672A5 (ja) | ||
JP2014519817A5 (ja) | ||
JP2008531463A5 (ja) |